Empowering Oncologists: How far can purpose and passion take you in cancer care? @drchoueiri.bsky.social oncodaily.com/dialogues/31... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EmpoweringOncologists

In 2023, the @fda.gov approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD. Now, @drchoueiri.bsky.social, director of our Lank Center for Genitourinary Oncology, and team are working to expand its clinical use.

@drchoueiri.bsky.social‬ discusses promising results from the phase 1 ARC-20 study, exploring the combination of Casdatifan and cabozantinib in patients with previously treated clear cell renal cell carcinoma. #ASCO25

1 week left to support @danafarber.bsky.social & Gronk Nation Youth Foundation! Help us finish strong + take on @RobGronkowski! 🎟️ $187+ = ticket to the event 🏈 $100+ = chance to win signed Gronk football 👀 Gronk, Edelman, Ninkovich, Chung 📅 Deadline: May 20 🔗 charity.pledgeit.org/pickleball/t...

“I can imagine no heroism greater than motherhood." - Happy Mothers day mom and all the mothers in the world ! #HappyMothersDay2025

We’re getting ready to wrap up #AACR25 today, but not before once again congratulating @danafarbernews.bsky.social’s Matthew Meyerson, MD, PhD, FAACR, @drchoueiri.bsky.social and Alice T. Shaw, MD, PhD, for receiving @theaacr.bsky.social 2025 Scientific Achievement Awards. bit.ly/4j7m8om#AACR25

Thank you @theaacr.bsky.social for the Waun Ki Hong Award! My talk will be addressing Precision Medicine in Renal Cell Carcinoma. See you in Chicago! cc: @danafarber.bsky.social

Our own @danafarber.bsky.social Dr. @NarjustFlorezMD is running for @iaslc.bsky.social Board. Let us support NJ! @narjustflorezmd.bsky.social @danafarbernews.bsky.social

Thank you @theaacr.bsky.social for this honor !

“Our focused efforts are yielding results that are helping patients today and guiding our research towards more advances in the future,” says @drchoueiri.bsky.social. Learn about the research advancements our Lank Center for Genitourinary Oncology has made this past year.

💬 Transatlantic Exchange : interview croisée du Dr @drchoueiri.bsky.social & du Pr Karim Fizazi. Le 19 mars s’est tenue à Paris la 4e édition des Transatlantic Exchanges, une journée scientifique co-organisée par @gustaveroussy.fr et le @danafarber.bsky.social. ⬇

“It may be that the satisfaction I need depends on my going away, so that when I've gone and come back, I'll find it at home”—Rumi, 13th century

Another year, another #pickeball tournament with our good friend Rob Gronkowski #DaGronk to benefit our Research and Gronk Nation Youth Foundation. Join me and donate at: charity.pledgeit.org/pickleball/@to… #curecancere#beatgronknk

This weekend, thanks to the support of the @redsox.com, @danafarber.bsky.social & @thejimmyfund.bsky.social gathered @fenwaypark.bsky.social to celebrate the impact of our Campaign. We celebrated our donors who help us defy Cancer together !

Yesterday, @drchoueiri.bsky.social and Karim Fizazi, MD, PhD, kicked off The Fourth Transatlantic Exchange in Oncology: Radiopharmaceutical Therapy Meets Oncology. Learn more about the collaborative event with @gustaveroussy.fr: bit.ly/42fC69Z

Thank you @TownofWestwood and Lenny Strauss for highlighting our @PanMass journey the past several years, both @mvmombo and I. We are committed @DanaFarber to end Cancer! hometownweekly.net/westwood/dr-ch… Our @CowbellTeam Link for donations to cure Cancer: teammorecowbell.com/

Happy International Women’s day to the wonderful GU Oncology Women’s @danafarber.bsky.social (front row)

Our new paper in JITC with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. jitc.bmj.com/content/13/3/e… @danafarber.bsky.social jitc.bmj.com/content/13/3...64

Promising results: Adjuvant neoantigen vaccination prevents recurrence of kidney cancer bit.ly/3EUpSKG  @danafarber.bsky.social  @braunmdphd.bsky.social  @yalecancer.bsky.social  @drchoueiri.bsky.social

#GU25 was an outstanding @ascocancer.bsky.social meeting: catching up with friends/ colleagues, watching mentees grow, learn up-to-date GU cancers management, and presenting a new HIF-2 inhibitor (casdatifan) data. Energized! The future is bright! @danafarber.bsky.social @jrgralow.bsky.social

Great @ascocancer.bsky.social #GU25 catching up with many friends ! @jrgralow.bsky.social

Updated results from the phase 2 LITESPARK-003 study on belzutifan + cabozantinib in advanced ccRCC patients! 📊💡 Key insights into combination therapy and improved outcomes @ascocancer.bsky.social #GU25 @drchoueiri.bsky.social

Great to have @drchoueiri.bsky.social stop by our poster @ascocancer.bsky.social #GU25! Appreciate the insightful discussion and your time.

A customized kidney cancer vaccine made from patients’ tumors looked promising in a small study, @drchoueiri.bsky.social et al report in @nature.com. None of the 9 treated people experienced recurrence. Larger trial of mRNA vaccine underway. www.cancerhealth.com/article/pers...

In @statnews.com: 9 patients w/advanced kidney cancer who received an experimental vaccine tailored to tumors’ specific mutations mounted an immune response & remained cancer-free for 3 years. @drchoueiri.bsky.social of @danafarber.bsky.social explains the early-phase clinical trial. bit.ly/4aNK9xs

It's an incredible proof-of-principle! Fantastic work led by @drchoueiri.bsky.social Personalised cancer vaccines in the adjuvant setting!! www.nature.com/articles/d41...

A personalized cancer vaccine to prevent the return of high-risk kidney cancer @nature.com @braunmdphd.bsky.social @drchoueiri.bsky.social www.nature.com/articles/d41... www.nature.com/articles/s41...

Successful anti-cancer immune responses reported in phase 1 trial of a personalized cancer vaccine for #kidneycancer. Research in Nature led by @drchoueiri.bsky.social #PatrickOtt #CatherineWu #DerinKeskin (all of @danafarber.bsky.social) and David Braun of @yalecancer.bsky.social. bit.ly/3CDIT3n

Congrats @drchoueiri.bsky.social! Tremendous translational clinical trial with truly elegant science supporting this concept! Excited for the larger studies ongoing for patients in critical need of curative therapies. @theaacr.bsky.social @helloeacr.bsky.social @ascocancer.bsky.social

Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer www.nature.com/articles/s41... This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab www.nature.com/articles/s41...

🚨 Don’t miss the 2025 Transatlantic Exchange in Oncology! 🌍 Join us in Paris or online on March 19, as world-leading experts from @danafarber.bsky.social & Gustave Roussy to discuss innovations in radiopharmaceutical therapy. Register now: ms.spr.ly/6048UEwTp @medscape.com @servier.bsky.social

We had the pleasure to host our friend Dr. Humaid Al Shamsi from Emirati Society of Oncology at the @danafarber.bsky.social Booth during #ArabHealth2025

Join us for Intersections: Personalized Risk Assessment for Gastrointestinal Cancers with Mary Uan-Sian Feng, MD. Gain insights on risk scores, biomarkers for screening, and more cutting-edge updates at #GI25!

This GU oncology family — wonderful first #AUC3 consensus conference! @drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social

#AUC3 tackling hard questions in bladder and kidney cancers

Drs. #NaomiHaas #HansHammers debate locally advanced #kidneycancer and use of periop immunotherapy. Grading, staging, and prediction of risk/benefit leads to rigorous shared decision making with our patients. @drchoueiri.bsky.social #AUC3

Launching #AUC3 in Miami, consensus across kidney and bladder cancers. From small steps to significant scientific advances that change our patients’ lives. @drchoueiri.bsky.social #MontyPal #RanaMcKay #JonathanRosenberg

Closing day of attending  @brighamandwomens.bsky.social @Dana- with this year’s amazing BWH/BIDMC housestaff!  Breadth of cases to learn from in and outside #GUoncology and comfort zone! Now, taking a moment with Wally (Red Sox) at end of rotation!

Belzutifan plus cabozantinib shows promising antitumor activity in patients with clear-cell renal cell carcinoma not previously treated - research led by @danafarber.bsky.social’s @drchoueiri.bsky.social and published in The Lancet Oncology. bit.ly/4jciWIR

Our paper in ESMO open about NK cells dysfunction in Kidney Cancer www.sciencedirect.com/science/arti...

Our society ASCO resources for disaster assistance with LA fires society.asco.org/resources-di...

people.com/doctor-famil... Leadership at its best ! In @peoplemag.bsky.social @cityofhope.bsky.social

Our 1st translational paper in 2025 now in Nature Cancer —summary Figure attached www.nature.com/articles/s43...

In Memory of Dr Felix Feng, our beloved friend and a giant in prostate cancer @ericsmall.bsky.social @ucsfcancer.bsky.social www.sciencedirect.com/science/arti...

www.nature.com/articles/d41... The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !

Top 5 Prostate Cancer Trials of 2024 by Toni Choueiri @drchoueiri.bsky.social @theaacr.bsky.social oncodaily.com/science/215325 #AACR #ARANOTEtrial #Cancer #OncoDaily #Oncology #ProstateCancer #Medicine #Health

It was a white Christmas!

FINAL Overall Results from Phase III RCT JAVELIN RENAL 101 in First-Line metastatic Kidney Cancer is now published in Annals of Oncology! www.annalsofoncology.org/callback?red...